Neuro/psycho-oncology Flashcards
(68 cards)
incidence of brain tumours?
15 cases /100,000 population/ year
prevalence of brain tumours
11,000 new cases per year
how many brain tumours per year are gliomas
5000
most common cancers
breast
lung
large bowel
prostate
primary brain tumours
meningioma
glioma
glioneuronal
neuroepithelial
pituitary
primary CNS
types of gliomas
glioblastoma multiforme
low grade gliomas
ependymoma (rare)
what are the two types of low grade gliomas
astrocyteoma
oligodendroglioma
WHO grading of extrinsic meningiomas
grade 1 (most common)
grade 2 (atypical and often post radiotherapy)
grade 3 (very rare and a poor prognosis)
what are two examples of intrinsic brain tomours
glioma
lymphoma
WHO grading of intrinsic gliomas
grade 1 (pilocytic astrocytoma)
grade 2 (oligodendroglioma or astrocytoma)
grade 3 (anaplastic astrocytoma or anaplastic oligodendroglioma
grade 4 (glioblastoma multiforme)
presentation and sx of diffuse astrocytoma
asymptomatic
seizures
raised ICP
focal neurological deficit
cognitive decline
personality change
likelihood of seizures in patients with brain tumours
40-60%
likelihood of seizures in patients with low grade gliomas
65-95%
likelihood of seizures in high grade gliomas
12-255
likelihood of seizures in patients with mets
25%
likelihood of seizures in pt with meningiomas
25%
sx of raised ICP
headache (worse in morning)
vomiting
diplopia
drowsiness
confusion
unsteady
hiccoughs
cushings triad - high bp, low pulse, respiration
focal neurological deficit
focal loss of function over days to weeks of limbs, eyes and face
cognitive decline/ personality change (esp. from tumours affecting the temporal and frontal lobes)
which factors increase survival
surgery (extent of resection, gliolan, dafer surgeries eg. intraoperative MRI)
oncology tx (temozolamide)
molecular pathology
Gliolan
Gliolan is a fluorescent dye, indicated in adults for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV)
temozolomide for (high grade) glioblastoma
follow up after 28 months
26.5% survival rate with radiotherapy plus temozolomide vs 10.4% survival rate with radiotherapy alone
DC vaccine
dendritic cell vaccine, is a type of cancer vaccine that utilizes the body’s own immune cells (dendritic cells) to recognize and attack cancer cells
molecular pathology
methylation status predicts response to chemo
methylated patients respond better to temozolomide
stupp protocol
It consists of radiation therapy and concomitant chemotherapy with temozolomide
This therapy resulted in a significant survival improvement at 2 years:
26.5% vs 10.4%